KD6005

KD6005 is an investigational biological product currently in phase 1 clinical development for the treatment of rheumatoid arthritis. The drug is being evaluated for its safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics in both healthy participants and patients with rheumatoid arthritis. It is administered as a subcutaneous injection. The precise mechanism of action has not been disclosed publicly as of June 2025. KD6005 is being developed by Shanghai Celgen Bio-pharmaceutical and Shanghai Kangdai Biomedical Technology (also referred to as Shanghai Kanda Biotechnology). Its primary therapeutic area is immune system diseases, specifically targeting skin and musculoskeletal disorders such as rheumatoid arthritis[1][2][3][4][9].